Next Article in Journal
Reclaiming the Microbial Battlefield: Adjuvant Strategies to Overcome Antibiotic Resistance
Previous Article in Journal
Process-Driven Acetate-Based Lipid Production by the Oleaginous Yeast Lipomyces starkeyi
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Taha et al. Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom. Microorganisms 2025, 13, 1933

by
Mostafa Waleed Taha
1,
Danielle J. C. Fenwick
2,
Emma C. L. Marrs
2 and
Abdul Shakoor Chaudhry
1,*
1
School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
2
Microbiology Research Department, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
*
Author to whom correspondence should be addressed.
Microorganisms 2026, 14(3), 607; https://doi.org/10.3390/microorganisms14030607
Submission received: 28 February 2026 / Accepted: 28 February 2026 / Published: 9 March 2026
(This article belongs to the Section Food Microbiology)
In the original publication [1], there was a mistake in the column “Observed Viable Plate Counts (Mean ± SD)” of Table 2. Details and viable counts of commercial poultry probiotic products and Table 3. Details and viable counts of commercial human probiotic products as published. The SD values were presented in a truncated format and should appear as full SD values. The corrected tables appear below.
Table 2. Details and viable counts of commercial poultry probiotic products.
Table 2. Details and viable counts of commercial poultry probiotic products.
Product CodeSpecies Declared on the LabelDeclared Label Total (CFU/g)MALDI-TOF MS ID 2Observed Viable Plate Counts
(Mean ± SD) 3
P3Bacillus subtilis2.5 × 107Bacillus spp.1.375 × 107 ± 2.06 × 106
P4Bacillus subtilis3 × 108Bacillus spp.1.900 × 108 ± 1.82 × 107
P5Bacillus subtilis2 × 109Bacillus spp.1.400 × 1010 ± 2.58 × 109
P9Bifidobacterium animalisRatio 1 3/10Bifidobacterium animalis1.300 × 108 ± 2.58 × 107
Lactobacillus salivariusRatio 1/10Ligilactobacillus salivarius3.200 × 107 ± 3.65 × 106
Enterococcus faeciumRatio 6/10Enterococcus faecium1.055 × 109 ± 4.43 × 107
Total bacteria1 × 109Total bacteria1.212 × 109 ± 4.47 × 107
P10Enterococcus faecium2 × 1010Enterococcus faecium5.800 × 1010 ± 4.54 × 109
P11Bacillus subtilis2 × 108Bacillus spp.5.950 × 108 ± 3.10 × 107
P12Bifidobacterium animalisRatio 1 3/10Bifidobacterium animalis1.080 × 107 ± 1.48 × 106
Lactobacillus salivariusRatio 1/10Ligilactobacillus salivarius1.375 × 106 ± 2.21 × 105
Enterococcus faeciumRatio 6/10Enterococcus faecium5.300 × 108 ± 4.32 × 107
Total bacteria2 × 108Total bacteria5.418 × 108 ± 4.22 × 107
1 For products P9 and P12, the manufacturer declared the total CFU per gram of product but did not specify individual CFU counts for each bacterial species. Instead, the label listed each species as a ratio of the total bacterial population. 2 Identification of isolates by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. 3 Mean ± standard deviation per gram. Observed means are based on n = 3 replicates for multi-species products and n = 4 for single-species products.
Table 3. Details and viable counts of commercial human probiotic products.
Table 3. Details and viable counts of commercial human probiotic products.
Product CodeFormSpecies Declared on the LabelDeclared Label Total (CFU/Form 1)MALDI-TOF MS ID 3Observed Viable Plate Counts
(Mean ± SD) 4
P1TabletsLactobacillus acidophilus2 × 1011NANo CFU detected 2
P2CapsuleLactobacillus acidophilusND 5Lactobacillus acidophilus3.483 × 109 ± 2.76 × 108
Bifidobacterium animalisNDBifidobacterium animalis6.533 × 108 ± 3.51 × 107
Bifidobacterium bifidumND
Total bacteria1 × 1010Total bacteria4.137 × 109 ± 2.96 × 108
P6CapsulesLactobacillus acidophilusNDLactobacillus acidophilus3.300 × 109 ± 1.00 × 108
Lactobacillus salivariusNDLactobacillus salivarius2.067 × 106 ± 4.61 × 105
Bifidobacterium animalisNDBifidobacterium animalis2.100 × 107 ± 2.00 × 106
Lactobacillus BulgaricusND
Total bacteria3 × 109Total bacteria3.320 × 109 ± 1.01 × 108
P7CapsulesLactobacillus acidophilusNDLactobacillus acidophilus5.667 × 109 ± 3.05 × 108
Bifidobacterium bifidumNDBifidobacterium bifidum8.100 × 108 ± 4.35 × 107
Total bacteria1 × 1010Total bacteria6.477 × 109 ± 3.36 × 108
P8Chewable TabletsLactobacillus acidophilusNDLactobacillus acidophilus5.533 × 108 ± 1.52 × 107
Bifidobacterium animalisNDBifidobacterium animalis2.800 × 107 ± 1.00 × 106
Total bacteria1 × 109Total bacteria5.813 × 108 ± 1.56 × 107
1 Per form (capsule or tablet, as specified in the “Form” column, except for P1, where label showed counts per gram). 2 For product P1, viability testing was conducted using two sample types: (i) a single tablet, and (ii) a composite of seven tablets equivalent to 1 g, as the label declared viable count per gram. No colony growth was observed in either case on any agar medium. 3 Identification of isolates by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. 4 Mean ± standard deviation per form. Observed means are based on n = 3 replicates for multi-species products and n = 4 for single-species products. 5 ND = Not declared on label; the manufacturer provided a total count but did not specify counts for individual species.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Taha, M.W.; Fenwick, D.J.C.; Marrs, E.C.L.; Chaudhry, A.S. Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom. Microorganisms 2025, 13, 1933. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Taha, M.W.; Fenwick, D.J.C.; Marrs, E.C.L.; Chaudhry, A.S. Correction: Taha et al. Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom. Microorganisms 2025, 13, 1933. Microorganisms 2026, 14, 607. https://doi.org/10.3390/microorganisms14030607

AMA Style

Taha MW, Fenwick DJC, Marrs ECL, Chaudhry AS. Correction: Taha et al. Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom. Microorganisms 2025, 13, 1933. Microorganisms. 2026; 14(3):607. https://doi.org/10.3390/microorganisms14030607

Chicago/Turabian Style

Taha, Mostafa Waleed, Danielle J. C. Fenwick, Emma C. L. Marrs, and Abdul Shakoor Chaudhry. 2026. "Correction: Taha et al. Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom. Microorganisms 2025, 13, 1933" Microorganisms 14, no. 3: 607. https://doi.org/10.3390/microorganisms14030607

APA Style

Taha, M. W., Fenwick, D. J. C., Marrs, E. C. L., & Chaudhry, A. S. (2026). Correction: Taha et al. Assessing Bacterial Viability and Label Accuracy in Human and Poultry Probiotics Sold in the United Kingdom. Microorganisms 2025, 13, 1933. Microorganisms, 14(3), 607. https://doi.org/10.3390/microorganisms14030607

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop